16:36:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 Ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2023-07-19 11:30:00

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Desmopressin Newbury 60, 120 & 240 mcg sublingual tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.

“Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. Newbury is one of very few companies offering this complex niche peptide product which demonstrates our ability to provide highly differentiated, value-added niche products for our markets. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” Says Mr. Lars Minor, CEO of Newbury.

Nocturia is defined as “the complaint that the individual has to wake at night one or more times for voiding (i.e. to urinate)”. Nocturia becomes more common with age. More than 50 percent of men and women over the age of 60 have been measured to have nocturia in many communities.

The brand sold over €10 mio in Scandinavia between June 2022 and May 2023, according to DLMI.